Evidence map›Paper›PMID 39351369›Full record

ArticlePeerJ2024

Early cancer screening surveillance in one medical center of China.

Ying Yang, Peng Du, Xiaolu Hou, Kun Yan, Ying Dai, ZhiYing Sun, Qi Wu, Shijie Li, Yan Yan, Zhilong Wang and 7 more

Abstract read
In one paragraph

Article in PeerJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ying YangKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), The VIP-II Gastrointestinal Cancer Division of Medical Department, Peking University Cancer Hospital & Institute, Beijing, China.
Peng DuKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), Department of Urology, Peking University Cancer Hospital & Institute, Beijing, China.
Xiaolu HouWestern Beijing Cancer Hospital, Beijing, China.
Kun YanKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), Department of Ultrasonography, Peking University Cancer Hospital & Institute, Beijing, China.
Ying DaiKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), Department of Ultrasonography, Peking University Cancer Hospital & Institute, Beijing, China.
ZhiYing SunKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), Department of Ultrasonography, Peking University Cancer Hospital & Institute, Beijing, China.
Qi WuKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), Department of Endoscopy, Peking University Cancer Hospital & Institute, Beijing, China.
Shijie LiKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), Department of Endoscopy, Peking University Cancer Hospital & Institute, Beijing, China.
Yan YanKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), Department of Endoscopy, Peking University Cancer Hospital & Institute, Beijing, China.
Zhilong WangKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), Department of Radiology, Peking University Cancer Hospital & Institute, Beijing, China.
Liping QiKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), Department of Radiology, Peking University Cancer Hospital & Institute, Beijing, China.
Mailin ChenKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), Department of Radiology, Peking University Cancer Hospital & Institute, Beijing, China.
Hong ZhengKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), Department of Gynecologic Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Weijiao GaoKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), Department of Gynecologic Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Min GaoKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), Department of Gynecologic Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Weicheng XueKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China.
Xiaodong ZhangKey laboratory of Carcinogenesis and Translational Research (Ministry of Education, China), The VIP-II Gastrointestinal Cancer Division of Medical Department, Peking University Cancer Hospital & Institute, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Cancer screening aims to detect and treat malignant lesions at an early stage and to prolong patients' lifetime. There is still a lack of effective cancer screening programs in China. We initiated a screening project in 2018 and this study presented the cancer screening status in China. Methods: We conducted a cross-sectional study in one cancer-care medical center of China. The screening program included routine blood tests, plasma tumor markers, gastric endoscopy, colonoscopy, ultrasound, and computed tomography (CT) scans. Screening results were presented as sensitivity, specificity and positive predictive values (PPVs). Results: Twenty-three (1.46%) out of 1,576 participants were eventually diagnosed with malignant tumors or high-grade intraepithelial neoplasia (HGIN). A family history of malignancy (78.26% in diagnosed cancer and HGIN Conclusion: We emphasized risk stratification for early cancer screening, such as a family history of cancer. The survey illustrated that gastric endoscopy, colonoscopy, ultrasound, and lung CT for early cancer screening had high specificity, reasonable sensitivity, and PPV. We anticipated this report would motivate larger-sample studies to estimate the risk-to-benefit ratio of cancer screening and urge the establishment of a native Chinese screening project and even guidelines.

Indexed as

Early Detection of CancerAdultAgedBiomarkers, TumorChinaColonoscopyCross-Sectional StudiesFemaleHumansMaleMass ScreeningMiddle AgedNeoplasmsSensitivity and SpecificityTomography, X-Ray ComputedUltrasonographyBiomarkers, TumorEarly cancer screeningFamily history of malignancyPositive predictive valueSensitivitySpecificity

Identifiers

PMID39351369
PMCPMC11441387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.